Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer

Sharad A Ghamande, S. Lele, D. Marchetti, T. Baker, K. Odunsi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The purpose of the study is to assess the role of palliative chemotherapy with weekly paclitaxel in patients with persistent or recurrent advanced ovarian cancer. Twenty-eight patients with predominantly paclitaxel- and platinum-resistant ovarian cancer disease were treated with weekly paclitaxel at 80 mg/m2 for 6-8 weeks. In 25 patients (89.2%), this combination represented at least a third line of therapy and for 14 patients (50%) it was more than the fifth line. A clinical response rate of 50% (14 partial responses) was obtained in the 28 patients with evaluable disease. Five patients (17.9%) had stable disease and nine patients (32.1%) had progression of disease. In patients with stable disease or a response, the median progression-free interval was 6 months and overall median survival is 8+ months. All the responses in paclitaxel-resistant tumors were seen in patients with a paclitaxel-free interval of more than 12 months. This regimen is well tolerated with acceptable toxicity. These data suggest that weekly paclitaxel has considerable antitumor activity in heavily pretreated patients with platinum- and paclitaxel-resistant advanced ovarian cancer.

Original languageEnglish (US)
Pages (from-to)142-147
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume13
Issue number2
DOIs
StatePublished - Mar 1 2003

Fingerprint

Paclitaxel
Ovarian Neoplasms
Platinum
Ovarian Diseases
Disease Progression
Drug Therapy
Survival

Keywords

  • Platinum resistance
  • Recurrent ovarian cancer
  • Weekly paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. / Ghamande, Sharad A; Lele, S.; Marchetti, D.; Baker, T.; Odunsi, K.

In: International Journal of Gynecological Cancer, Vol. 13, No. 2, 01.03.2003, p. 142-147.

Research output: Contribution to journalArticle

Ghamande, Sharad A ; Lele, S. ; Marchetti, D. ; Baker, T. ; Odunsi, K. / Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer. In: International Journal of Gynecological Cancer. 2003 ; Vol. 13, No. 2. pp. 142-147.
@article{29a09c29c1fd4a778ee9850f40fc87ee,
title = "Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer",
abstract = "The purpose of the study is to assess the role of palliative chemotherapy with weekly paclitaxel in patients with persistent or recurrent advanced ovarian cancer. Twenty-eight patients with predominantly paclitaxel- and platinum-resistant ovarian cancer disease were treated with weekly paclitaxel at 80 mg/m2 for 6-8 weeks. In 25 patients (89.2{\%}), this combination represented at least a third line of therapy and for 14 patients (50{\%}) it was more than the fifth line. A clinical response rate of 50{\%} (14 partial responses) was obtained in the 28 patients with evaluable disease. Five patients (17.9{\%}) had stable disease and nine patients (32.1{\%}) had progression of disease. In patients with stable disease or a response, the median progression-free interval was 6 months and overall median survival is 8+ months. All the responses in paclitaxel-resistant tumors were seen in patients with a paclitaxel-free interval of more than 12 months. This regimen is well tolerated with acceptable toxicity. These data suggest that weekly paclitaxel has considerable antitumor activity in heavily pretreated patients with platinum- and paclitaxel-resistant advanced ovarian cancer.",
keywords = "Platinum resistance, Recurrent ovarian cancer, Weekly paclitaxel",
author = "Ghamande, {Sharad A} and S. Lele and D. Marchetti and T. Baker and K. Odunsi",
year = "2003",
month = "3",
day = "1",
doi = "10.1046/j.1525-1438.2003.13045.x",
language = "English (US)",
volume = "13",
pages = "142--147",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Weekly paclitaxel in patients with recurrent or persistent advanced ovarian cancer

AU - Ghamande, Sharad A

AU - Lele, S.

AU - Marchetti, D.

AU - Baker, T.

AU - Odunsi, K.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - The purpose of the study is to assess the role of palliative chemotherapy with weekly paclitaxel in patients with persistent or recurrent advanced ovarian cancer. Twenty-eight patients with predominantly paclitaxel- and platinum-resistant ovarian cancer disease were treated with weekly paclitaxel at 80 mg/m2 for 6-8 weeks. In 25 patients (89.2%), this combination represented at least a third line of therapy and for 14 patients (50%) it was more than the fifth line. A clinical response rate of 50% (14 partial responses) was obtained in the 28 patients with evaluable disease. Five patients (17.9%) had stable disease and nine patients (32.1%) had progression of disease. In patients with stable disease or a response, the median progression-free interval was 6 months and overall median survival is 8+ months. All the responses in paclitaxel-resistant tumors were seen in patients with a paclitaxel-free interval of more than 12 months. This regimen is well tolerated with acceptable toxicity. These data suggest that weekly paclitaxel has considerable antitumor activity in heavily pretreated patients with platinum- and paclitaxel-resistant advanced ovarian cancer.

AB - The purpose of the study is to assess the role of palliative chemotherapy with weekly paclitaxel in patients with persistent or recurrent advanced ovarian cancer. Twenty-eight patients with predominantly paclitaxel- and platinum-resistant ovarian cancer disease were treated with weekly paclitaxel at 80 mg/m2 for 6-8 weeks. In 25 patients (89.2%), this combination represented at least a third line of therapy and for 14 patients (50%) it was more than the fifth line. A clinical response rate of 50% (14 partial responses) was obtained in the 28 patients with evaluable disease. Five patients (17.9%) had stable disease and nine patients (32.1%) had progression of disease. In patients with stable disease or a response, the median progression-free interval was 6 months and overall median survival is 8+ months. All the responses in paclitaxel-resistant tumors were seen in patients with a paclitaxel-free interval of more than 12 months. This regimen is well tolerated with acceptable toxicity. These data suggest that weekly paclitaxel has considerable antitumor activity in heavily pretreated patients with platinum- and paclitaxel-resistant advanced ovarian cancer.

KW - Platinum resistance

KW - Recurrent ovarian cancer

KW - Weekly paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0037631528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037631528&partnerID=8YFLogxK

U2 - 10.1046/j.1525-1438.2003.13045.x

DO - 10.1046/j.1525-1438.2003.13045.x

M3 - Article

VL - 13

SP - 142

EP - 147

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -